1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
69B6E79135E1D67DD00258B9000294EB8
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-medical-affairs-product-launch-in-metabolic-diseases-roles-collaboration-evolution?opendocument
18
19opendocument
203.235.145.252
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Launch Optimization

Medical Affairs Product Launch in Metabolic Diseases Segment: Roles, Collaboration, and Evolution

ID: 5827


Features:

7 Info Graphics

15 Data Graphics

300+ Metrics

18 Narratives


Pages/Slides: 31


Published: 2024


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Medical Affairs Product Launch in Metabolic Diseases Segment: Roles, Collaboration, and Evolution”

STUDY OVERVIEW

Metabolic disease product launches require Medical Affairs to take on redefined roles and collaborative efforts to ensure new treatments effectively meet patient needs and market expectations. As this function grows, Medical Affairs must take the lead in bridging the gap between scientific innovation and real-world patient care, driving launch success by facilitating communication and coordination across multiple stakeholders.

Best Practices, LLC undertook this benchmarking research to investigate the evolving role of Medical Affairs in metabolic diseases, focusing on leadership, cross-functional collaboration, and adaptation to new scientific developments. The research delves into how Medical Affairs teams are fostering innovation and aligning internal and external stakeholders to ensure new therapies are positioned for optimal impact.

KEY TOPICS

  • Medical Leadership Roles and Launch Activity Effectiveness in Metabolic Diseases Segment
  • Ensuring Cross-functional Alignment and Collaboration in Metabolic Disease Product Launches
  • Adopting to Ongoing Changes in Medical Landscape

KEY METRICS

  • Medical Affairs’ leadership role in metabolic disease product launches
  • Optimizing Medical Affairs launch activities in metabolic diseases segment
  • Improvement areas for Medical Affairs around metabolic disease product launches
  • Medical Affairs’ internal collaboration to ensure successful metabolic disease product launches
  • Medical Affairs’ cross-functional team role in metabolic diseases segment

SAMPLE KEY FINDINGS

  • Internal Group Collaboration: Medical collaborates early and often with cross-functional launch teams (89%) through clearly defined roles, responsibilities, and expectations (68%) to ensure successful metabolic product launches.

METHODOLOGY

This benchmarking study engaged 21 Medical leaders from 16 leading life sciences organizations. The study insights are drawn primarily from Medical Directors and upper management executives, representing nearly 80% of the benchmark class.

Industries Profiled:
Pharmaceutical; Consulting; Biopharmaceutical; Communications; Consumer Products; Biotech; Health Care; Medical Device


Companies Profiled:
AstraZeneca; BIAL; Boehringer Ingelheim; Cipla; EMD Serono; Eurofarma; MEDiSTRAVA; Matinas BioPharma; Merck KGaA; NexGen Healthcare Communications; Novartis; Pfizer; Pixacore; Sandoz; Takeda Pharmaceuticals; Terumo BCT: Terumo Blood and Cell Technologies

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.